SYMPHOGEN
Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.
SYMPHOGEN
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2000-01-01
Address:
Lyngby, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.symphogen.com
Total Employee:
101+
Status:
Active
Contact:
45 45 26 50 50
Email Addresses:
[email protected]
Total Funding:
375.22 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Domain Not Resolving SSL By Default Euro Google Analytics WordPress DNSSEC DMARC
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
KSQ Therapeutics
KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
System-c bioprocess
System-c bioprocess is a biotechnology company that provides fermentation, cell culture, screening, and bioprocessing services.
Union Agener
Union Agener is a biotechnology unit that produces biotech products to increase milk production.
Current Advisors List
Current Employees Featured
Founder
Investors List
PKA
PKA investment in Debt Financing - Symphogen
Novo Holdings
Novo Holdings investment in Debt Financing - Symphogen
Novo Holdings
Novo Holdings investment in Private Equity Round - Symphogen
Danica Pension
Danica Pension investment in Private Equity Round - Symphogen
PKA
PKA investment in Private Equity Round - Symphogen
Novo Holdings
Novo Holdings investment in Venture Round - Symphogen
Essex Woodlands Healthcare Partners
Essex Woodlands Healthcare Partners investment in Venture Round - Symphogen
PKA
PKA investment in Venture Round - Symphogen
Essex Woodlands Healthcare Partners
Essex Woodlands Healthcare Partners investment in Venture Round - Symphogen
GenenFUND
GenenFUND investment in Private Equity Round - Symphogen
Official Site Inspections
http://www.symphogen.com Semrush global rank: 5.84 M Semrush visits lastest month: 1.24 K
- Host name: linux1.curanet.dk
- IP address: 94.231.106.219
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "Symphogen"
Who we are - Symphogen
Symphogen is inspired by nature, led by science, and driven by people. We work with antibodies, the human body’s natural defense system designed to resist and fight disease. Every day, we … See details»
Symphogen - Wikipedia
Symphogen is a biotechnology company located in Copenhagen, Denmark that develops protein drugs based on recombinant monoclonal antibody mixtures. These drugs are different from the polyclonal antibodies, as each antibody in the mixture is produced from one carefully selected clone. Their three main areas of therapeutic research are immunoglobulin replacement, cancer, and infectious …See details»
Symphogen - Org Chart, Teams, Culture & Jobs | The Org
View Symphogen's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. See details»
Symphogen Org Chart + Executive Team - The Official …
The org chart of Symphogen contains its 10 main executives including Christophe Thurieau and Michael Herbst. See details»
Symphogen - Crunchbase Company Profile & Funding
Symphogen is a biotechnology company that produces recombinant polyclonal antibody drugs for disease treatment and prevention. See details»
Symphogen - ida.dk
Symphogen is a R&D organization with approximately ~150 employees located in Ballerup, Denmark. Servier is a global pharmaceutical group governed by a non-profit foundation and … See details»
Frontpage - Symphogen
Symphogen is the Antibody Center of Excellence in the Servier Group. We are primarily focused on oncology and immune oncology. We have a highly efficient antibody discovery and research platform supported by comprehensive early … See details»
Servier signed a definitive agreement to acquire Symphogen,
Apr 3, 2020 Symphogen will operate as a standalone organization within the Servier Group, maintain its headquarters in Ballerup, Denmark, and continue to rely on its current and … See details»
Symphogen - Gilde Healthcare
Symphogen is a leader in the development of antibody mixtures to improve the treatment of cancer. Symphogen’s technology is uniquely suited for targeting multiple molecules, which is … See details»
Symphogen Company Profile - Office Locations, Competitors
Symphogen has 5 employees across 2 locations and $387.2 m in total funding,. See insights on Symphogen including office locations, competitors, revenue, financials, executives, … See details»
Company - Symphogen
Symphogen is the Antibody Center of Excellence in the Servier Group. We apply our highly efficient antibody platform and capabilities in the discovery and early development of … See details»
Symphogen - Senior Management Team | The Org
The Senior Management Team at Symphogen provides strategic leadership and direction to the company, ensuring alignment with its mission to develop innovative antibody oncology … See details»
Servier Acquires Symphogen - Pharma's Almanac
Apr 3, 2020 Symphogen will operate as a standalone organization within the Servier Group, maintain its headquarters in Ballerup, Denmark, and continue to rely on its current and … See details»
Symphogen continues to fight for a breakthrough after 25 years:
May 28, 2025 Symphogen has undergone significant changes in its 25-year life. CEO Malin Carlsson tells MedWatch about failed attempts, a strong company spirit and a French acquisition. See details»
Engagement & motivation - Symphogen
We achieve success when we focus our attention on how to develop from good to great and how to stay at the top as an organization and as an individual. Once every third year we ask … See details»
Symphogen - Contacts, Employees, Board Members, Advisors
Symphogen is a biotechnology company that produces recombinant polyclonal antibody drugs for disease treatment and prevention. See details»
Values - Symphogen
We are driven by four core values in our daily work to develop innovative and meaningful antibody therapies against serious diseases. We strive to create the best possible environment for our … See details»
News - Symphogen
Symphogen was founded in 2000 – and in 2020 Symphogen became a member of Servier Pharmaceutical as the R&D Antibody Center of Excellence. Founded to serve health 70 years … See details»
Symphogen - Funding, Financials, Valuation & Investors
Symphogen is a biotechnology company that produces recombinant polyclonal antibody drugs for disease treatment and prevention. See details»
Pipeline - Symphogen
Over the years, Symphogen has demonstrated our ability to deliver unique antibodies and we have advanced a number of projects from target to lead and further into clinical phases. In … See details»